Home Newsfeeds Deutsche Bank Maintains Buy on Micron Technology, Lowers Price Target to $60

Deutsche Bank Maintains Buy on Micron Technology, Lowers Price Target to $60

Deutsche Bank analyst Sidney Ho maintains Micron Technology (NASDAQ:MU) with a Buy and lowers the price target from $68 to $60.

byBenzinga Newsdesk

September 30, 2022

1 minute read

Deutsche Bank analyst Sidney Ho maintains Micron Technology (NASDAQ:MU) with a Buy and lowers the price target from $68 to $60.

Immunovant Announces IMVT-1402, A Next Generation Anti-FcRn; Plan To Submit IND And Initiate Phase 1 Study In Early 2023 With Initial Data Expected In Mid-2023.

By Benzinga Newsdesk

September 28, 10:47 AM

In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. Plan to submit IND and initiate Phase 1 study in early 2023

IMVT

Goldman Sachs Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $15

By Benzinga Newsdesk

August 10, 8:37 AM

Goldman Sachs analyst Salveen Richter maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $20 to $15.

ACAD

Analysts Launch Coverage On Marex Group Stock: What You Need To Know

By Vaishali Prayag

May 20, 2:50 PM

Marex Group shares are starting to gain positive momentum following the company's IPO last month. Several analyst firms initiated coverage on the stock on Monday.

MRX

Nvidia Backed AI Start-Up CoreWeave Lands New $1.1B Funding – What’s On The Cards?

By Shivani Kumaresan

May 1, 2:16 PM

CoreWeave, a cloud-computing firm backed by NVIDIA, has secured $1.1 billion in new funding, led by Coatue, with participation from Magnetar, who led the last primary round, as well as Altimeter Capital, Fidelity Management & Research Company, and Lykos Global Management.

AMZN

Deutsche Bank Maintains Buy on Micron Technology, Lowers Price Target to $60

Related Posts

Immunovant Announces IMVT-1402, A Next Generation Anti-FcRn; Plan To Submit IND And Initiate Phase 1 Study In Early 2023 With Initial Data Expected In Mid-2023.

Goldman Sachs Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $15

Analysts Launch Coverage On Marex Group Stock: What You Need To Know

Nvidia Backed AI Start-Up CoreWeave Lands New $1.1B Funding – What’s On The Cards?